MedTrace Logo

Characteristics of Prader-Willi Syndrome and Early-onset Morbid Obesity

NCT00375089 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 392

Last updated 2014-09-22

No results posted yet for this study

Summary

Prader-Willi syndrome (PWS) is a rare genetic disorder that affects about 1 in 14,000 people in the United States. As the most commonly identified genetic cause of obesity, PWS is often confused with Early-onset Morbid Obesity (EMO). Individuals with EMO show some signs of PWS, but clinically do not have PWS. The purpose of this study is to evaluate the clinical features and genetic basis of PWS and EMO, and to determine how these conditions affect a person throughout a lifetime.

Conditions

Interventions

OTHER

Group 1

Individuals with Prader-Willi syndrome. Monitoring every 6 months.

OTHER

Group 2

Individuals with Early-onset Morbid Obesity.

Sponsors & Collaborators

  • Office of Rare Diseases (ORD)

    collaborator NIH

  • Rare Diseases Clinical Research Network

    collaborator NETWORK

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

    collaborator NIH

  • University of Florida

    lead OTHER

Principal Investigators

  • Arthur Beaudet, MD · Baylor College of Medicine

Eligibility

Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2014-01-31
Completion
2014-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00375089 on ClinicalTrials.gov